

1 fu

PATENT
ATTORNEY DOCKET NO.: 053665-5010-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Louis S. KUCERA et al.

Confirmation No.: 2151

Application No.: 09/844,201

Group Art Unit: 1623

Filed: April 27, 2001

Examiner: Howard Owens, Jr.

For: COMPOSITIONS AND METHODS OF
DOUBLE-TARGETING VIRUS
INFECTIONS AND CANCER CELLS

Attorney Docket No.: 053665-5010-01

**LETTER REGARDING INFORMATION DISCLOSURE STATEMENTS SUBMITTED
ON OCTOBER 12, 2004 AND AUGUST 23, 2003**

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Applicants note that when the Examiner initialed the Form PTO-1449 submitted with the Supplemental Information Disclosure Statement filed on October 12, 2004 (copy attached hereto) several references were not initialed. The Examiner alleges that, at least for reference C41, that the reference was not submitted. Applicants do not understand how some references cited on the Form PTO-1449 were not included. Applicants do note, however, that the Patent Office somehow separated the references from the Supplemental Information Disclosure Statement when the Supplemental Information Disclosure Statement was originally filed. Indeed, Applicants had to provide the Patent Office with another copy of the Supplemental Information Disclosure Statement and Form PTO-1449.

Applicants herewith submit another copy of each of the references not initialed by the Examiner but cited on the Form PTO-1449 submitted with Supplemental Information Disclosure Statement filed on October 12, 2004 along with a copy of the Supplemental Information Disclosure Statement initialed by the Examiner. Applicants respectfully request that the

Examiner consider the references, initial the Supplemental Information Disclosure Statement, and return the Supplemental Information Disclosure Statement to Applicants' attorney.

Applicants further note that the Information Disclosure Statement filed on August 23, 2003 was also not initialed by the Examiner. A copy of the August 23, 2003 Information Disclosure Statement is attached hereto. Applicants respectfully request the Examiner to initial the references cited on this Information Disclosure Statement.


No fee is believed to be due for this submission. If any fees are due, please charge the required fees to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: January 11, 2005

By:


Paul E. Dietze Reg. No. 45,627

CUSTOMER NO. 09629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Telephone: (202) 739-3000
Facsimile: (202) 739-3001

<p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>	ATTY DOCKET NO. 053665-5010-01	APPLICATION NO 09/844,201
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE April 27, 2001	GROUP 1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HO	A01	2,086,585	07/13/1937	Taub et al.	260	127	
	A02	2,087,132	07/13/1937	Taub et al.	260	127	
	A03	2,108,765	02/15/1938	Domagk	167	30	
	A04	2,209,383	07/30/1940	Bock	8	116	
	A05	2,439,969	04/20/1948	Fourneau	260	338	
	A06	2,445,393	07/20/1948	Fourneau	260	338	
	A07	2,513,747	07/04/1950	Sallman et al.	260	338	
	A08	2,606,909	08/12/1952	Blicke	260	338	
	A09	2,689,790	09/21/1954	Mowry et al.	71	2.7	
	A10	2,950,253	08/23/1960	Kling et al.	252	152	
	A11	3,054,678	09/18/1962	Michener et al.	99	150	
	A12	3,694,473	09/26/1972	Eibl et al.	260	403	
	A13	4,093,714	06/06/1978	Tolman et al.	424	180	
	A14	4,096,278	06/20/1978	Queuille	424	329	
	A15	4,119,714	10/10/1978	Kny et al.	424	199	
	A16	4,159,988	07/03/1979	Eibl et al.	260	340.9R	
	A17	4,221,732	09/09/1980	Oette et al.	260	403	
	A18	4,235,877	11/25/1980	Fullerton	424	89	
	A19	4,291,024	09/22/1981	Turcotte	424	180	
	A20	4,329,302	05/11/1982	Hanahan et al.	260	925	
	A21	4,426,525	01/17/1984	Hozumi et al.	546	22	
	A22	4,444,766	04/24/1984	Bosies et al.	424	211	
	A23	4,471,113	09/11/1984	MacCoss	536	29	
	A24	4,540,521	09/10/1985	Garst et al.	260	459	
	A25	4,619,917	10/28/1986	Lee et al.	514	77	
HO	A26	4,622,392	11/11/1986	Hong et al.	536	28.5	

EXAMINER

DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OCT 12 2004

TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

053665-5010-01

APPLICATION NO

09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE

April 27, 2001

GROUP

1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>h</i>	A27	4,661,509	04/28/1987	Gordon et al.	514	397	
	A28	4,724,232	02/09/1988	Rideout et al.	514	50	
	A29	4,797,479	01/10/1989	Shuto et al.	536	28.5	
	A30	4,816,450	03/28/1989	Bell et al.	514	25	
	A31	4,826,823	05/02/1989	Cook et al.	514	46	
	A32	4,835,263	05/30/1989	Nguyen et al.	536	27	
	A33	4,837,023	06/06/1989	Eibl	424	439	
	A34	4,841,039	06/20/1989	Chu et al.	536	29	
	A35	4,880,782	11/14/1989	Eckstein et al.	514	45	
	A36	4,921,951	05/01/1990	Shuto et al.	536	28.5	
	A37	4,997,761	03/05/1991	Jett-Tilton	435	375	
	A38	5,026,687	6/25/1991	Yarchoan et al.	514	45	
	A39	5,034,394	07/23/1991	Daluge	514	261	
	A40	5,138,045	08/11/1992	Cook et al.	536	27	
	A41	5,221,696	06/22/1993	Ke et al.	514	786	
	A42	5,496,546	03/05/1996	Wang et al.	424	78.36	
	A43	5,614,548	03/25/1997	Piantadosi et al.	514	440	
	A44	5,633,388	05/27/1997	Diana et al.	548	305.7	
	A45	5,770,584	06/23/1998	Kucera et al.	514	77	
	A46	5,830,905	11/03/1998	Diana et al.	514	322	
	A47	5,846,964	12/08/1998	Ozeki	514	182	
	A48	5,891,874	04/06/1999	Colacino et al.	514	234.5	
	A49	5,922,757	07/13/1999	Chojkier	514	458	
	A50	5,962,437	4/30/1999	Kucera et al.	514	77	
<i>h</i>	A51	6,030,960	02/29/2000	Morris-Natschke et al.	514	77	



EXAMINER

Amal Desai

DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 053665-5010-01	APPLICATION NO 09/844,201
APPLICANT Louis S. KUCERA et al.		
FILING DATE April 27, 2001		GROUP 1623

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>Ho</i>	B01	0 094 586	11/23/1983	EPO (English)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B02	0 109 255	05/23/1984	EPO (English)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B03	0 142 333	05/22/1985	EPO (English)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B04	0 145 303	06/19/1985	EPO (English)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B05	0 146 258	06/26/1985	EPO (English)	<i>/</i>	<i>/</i>		
	B06	0 252 310	01/13/1988	EPO	<i>/</i>	<i>/</i>		
<i>Ho</i>	B07	0 310 109	04/05/1989	EPO (English)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B08	0 335 396	04/10/1989	EPO (English)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B09	0 350 287	01/10/1990	EPO	<i>/</i>	<i>/</i>		
<i>Ho</i>	B10	0 348 859	01/03/1990	EPO (English)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B11	0 416 401	03/13/1991	EPO	<i>/</i>	<i>/</i>		
<i>Ho</i>	B12	0 434 450	06/26/1991	EPO (English)	<i>/</i>	<i>/</i>		
	B13	0 506 704	07/11/1991	EPO	<i>/</i>	<i>/</i>		
<i>Ho</i>	B14	0 632 048	01/04/1995	EPO (English)	<i>/</i>	<i>/</i>		
	B15	1,561,630	03/28/1969	France	<i>/</i>	<i>/</i>		
<i>Ho</i>	B16	199 14 474	10/07/1999	Germany (<i>abstract only</i>)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B17	37 26 945 A1	02/23/1989	Germany (<i>abstract only</i>)	<i>/</i>	<i>/</i>		
	B18	39 34 820 A1	04/25/1991	Germany	<i>/</i>	<i>/</i>		
<i>Ho</i>	B19	40 10 228 A1	10/02/1991	Germany (<i>abstract only</i>)	<i>/</i>	<i>/</i>		
<i>Ho</i>	B20	2 239 243 A	06/26/1991	Great Britain	<i>/</i>	<i>/</i>		

EXAMINER



DATE CONSIDERED


12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY DOCKET NO.

053665-5010-01

APPLICATION NO

09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE

April 27, 2001

GROUP

1623

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>Ho</i>	B21	42-13841	08/05/1967	Japan (<i>abstract only</i>)				
<i>Ho</i>	B22	61-238793	10/24/1986	Japan				
<i>Ho</i>	B23	1029312	01/31/1989	Japan				
	B24	49-100224	09/21/1974	Japan				
<i>Ho</i>	B25	08-268890	10/15/1996	Japan (<i>abstract only</i>)				
<i>Ho</i>	B26	10-101591	04/21/1998	Japan (<i>abstract only</i>)				
<i>Ho</i>	B27	90/00555	01/25/1990	WIPO				
<i>Ho</i>	B28	90/05736	05/31/1990	WIPO (English)				
<i>Ho</i>	B29	90/15601	12/20/1990	WIPO (English)				
<i>Ho</i>	B30	91/05558	05/02/1991	WIPO				
<i>Ho</i>	B31	91/09602	07/11/1991	WIPO <i>abstract only</i>				
<i>Ho</i>	B32	91/19726	12/26/1991	WIPO				
<i>Ho</i>	B33	91/18914	12/12/1991	WIPO (English)				
<i>Ho</i>	B34	92/03462	03/05/1992	WIPO (<i>abstract only</i>)				
<i>Ho</i>	B35	92/06192	04/16/1992	WIPO (English)				
<i>Ho</i>	B36	93/08807	05/13/1993	WIPO (English)				
<i>Ho</i>	B37	93/00910	01/21/1993	WIPO				
<i>Ho</i>	B38	93/16091	08/19/1993	WIPO				
<i>Ho</i>	B39	93/16092	08/19/1993	WIPO (<i>abstract only</i>)				
<i>Ho</i>	B40	93/17020	09/02/1993	WIPO (English)				
<i>Ho</i>	B41	93/21191	10/28/1993	WIPO (English)				
<i>Ho</i>	B42	WO 94/28908	12/22/1994	WIPO				
<i>Ho</i>	B43	WO 98/22496	5/28/1998	WIPO (English)				
<i>Ho</i>	B44	WO 98/17679	4/30/1998	WIPO (English)				
<i>Ho</i>	B45	WO 99/07734	2/18/1999	WIPO (English)				

EXAMINER

Howard [Signature]

DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

053665-5010-01

APPLICATION NO

09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE

April 27, 2001

GROUP

1623

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

HO	C01	Aggarwal, S. K. et al., "Synthesis and Biological Evaluation of Prodrugs of Zidovudine," <u>J. Med. Chem.</u> , 33, 1505-10, 1990
	C02	Alt M. et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Potent and Specific Inhibitors of Hepatitis C Viral Translation," <u>Archives of Virology</u> 142:589-599, 1997
	C03	Alt M. et al., "Specific Inhibition of Hepatitis C Viral Gene Expression by Antisense Phosphorothioate Oligodeoxynucleotides," <u>Hepatology</u> 22:707-717, September 1995
	C04	Amari et al., "Isolation of Experimental Anti-AIDS Glycerophospholipids by Micro-Preparative Reversed-Phase High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> , 590, 153-161, 1992
	C05	Anderson, L. J. et al., "Antigenic Characterization of Respiratory Syncytial Virus Strains with Monoclonal Antibodies," <u>Journal of Infectious Diseases</u> , 151:626-633, April 1985
	C06	Attwood, M. R. et al., "The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase," <u>Antiviral Chemistry and Chemotherapy</u> 10:259-273, September 1999
	C07	Berdel et al., "Cyto Toxicity of Thio Ether Lyso Phospho Lipids in Leukemias and Tumors of Human Origin," <u>Cancer Research</u> , Vol. 43, 5538-5543, 1983.
	C08	Berenguer, M. et al., "Hepatitis C Virus in the Transplant Setting," <u>Antiviral Therapy</u> 3(Suppl. 3):125-136, 1998
	C09	Boldanova, N. B. et al., "Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis," <u>Vopr. Med. Khim</u> , 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986)
	C10	Bosies, E. et al., "Preparation of Lecithin Analogs as Retrovirucides and Virucides," <u>Chemical Abstracts</u> , 115CA; 72142p, 1991
	C11	Chen, "Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents," Abstract <u>American Assoc. of Pharmaceutical Scientists</u> , Vol. 9, No. 10, 1992
	C12	Chu M. et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the Fungus <u>Penicillium Griseofulvum</u> ," <u>Bioorganic and Medicinal Chemistry Letters</u> 9:1949-1952, 1999
	C13	Chu M. et al., "Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor from <u>Streptomyces</u> sp.," <u>Tetrahedron Letters</u> 37:7229-7232, 1996
	C14	Coe et al., "Preparation of Nucleotide Mimics with Potent Inhibitory Activity Against HIV Reserve Transcriptase," <u>J. Chem. Soc. Perkin Trans 1</u> , 3378-3379, 1991.
	C15	Crompton, S. et al., "Novel Lipid Analogs with Cytostatic and Cytocidal Activity," <u>Anticancer Research</u> , Vol. 8, No. 6, pp. 1361-1366, Nov.-Dec. 1988
	C16	Daniel, L. W. et al., "Alkyl-Linked Diglycerides Inhibit Protein Kinase C Activation by Diacylglycerols," <u>Biochemical & Biophysical Research Communications</u> , 151, 291-97, Feb. 29, 1988
	C17	Dietzfelbinger, "Cytotoxic and Purging Effects of ET-18-OCH3 in Human Malignant Lymphoid Cell Lines in Vitro," Abstract 2472, <u>Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416, March 1990
HO	C18	Domawchowske J. B. et al., "Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis and Treatment," <u>Clinical Microbiology Reviews</u> , 12:298-309, April 1999

EXAMINER

Howard Davis

DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

053665-5010-01

APPLICATION NO

09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE

April 27, 2001

GROUP

1623

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

Ho	C19	Englund, J. A., "Prevention Strategies for Respiratory Syncytial Virus: Passive and Active Immunization," <u>J. Pediatr.</u> , 135:38-44, August 1999
	C20	Falsey A. R. et al., "Acute Respiratory Tract Infection in Daycare Centers for Older Persons," <u>J Am Geriatric Soc.</u> , 43:30-36, 1995
	C21	Falsey A. R. et al., "Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings," <u>J Am Geriatric Soc.</u> , 40:115-119, 1992
	C22	Fields, A. P. et al., "Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor," <u>Nature</u> , 333, 278-80, 19 May 1988
	C23	Galderisi U. et al., "Antisense Oligonucleotides as Therapeutic Agents," <u>Journal of Cellular Physiology</u> , 181:251-257, 1999
	C24	Glezen W. P. et al., "Risk of Primary Infection and Reinfection with Respiratory Syncytial Virus," <u>Am J Dis Child</u> , 140:543-546, 1986
	C25	Graham, F. L. et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5-DNA," <u>Virology</u> , Vol. 52, pp. 456-467, 1973
	C26	Guerguerian, A. et al., "Ribavirin in Ventilated Respiratory Syncytial Virus Bronchiolitis: a Randomized, Placebo-Controlled Trial," <u>Am J Resp Crit Care Med.</u> , 160:829-834, 1999
	C27	Hall C. B. et al., "Infectivity of Respiratory Syncytial Virus by Various Routes of Inoculation," <u>Infect Immun.</u> , 33:779-783, 1981
	C28	Hall, C. B. et al., "Nosocomial Respiratory Syncytial Virus Infections," <u>N Engl J Med.</u> , 293:1343-1346, 1975
	C29	Hall C. B. et al., "Respiratory Syncytial Virus Infections Within Families," <u>N Engl J Med</u> , 294:414-419, 1976
	C30	Hancock et al., "Analogues of Natural Lipids. VII. Synthesis of Cyclopentanoid Analogues of Phosphatidylcholine," <u>Journal of Lipid Research</u> , Vol. 23, 183-189, 1982
	C31	Harada, S. et al., "Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay," <u>Science</u> , 229, 563-566, 9 Aug. 1985
	C32	Hayashi et al., "Antitumor Activity of a Novel Nucleotide Derivative, 5'-(1,2 Dipalmitoyl-sn-glycero-3-phospho)-5-fluorouridine (TJ14026) on Murine Tumors," <u>Biol. Pharm. Bull.</u> , 16(8), 778-81, 1993
	C33	Henderson, F.W. et al., "Respiratory-Syncytial-Virus Infections, Reinfections, and Immunity: a Prospective, Longitudinal Study in Young Children," <u>N Engl J Med.</u> , 300:530-534, 1979
Ho*	C34	Himmelmann, "Studies on the Cross Resistance Pattern of Membrane-Toxic Lipids in Vitro," <u>Abstract 2448, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416, March 1990


EXAMINER

Howard Olson

DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5010-01	09/844,201
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE	GROUP
	April 27, 2001	1623

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
Ho	C35	Hirsch, M. S. et al., "Antiviral Agents," <u>Fields Virology</u> , Third Edition, Lippincott, Raven Publishers, page 431-466, 1996
Ho	C36	Hostetler, et al., "Antiviral Activity of Phosphatidyl-Dideoxycytidine in Hepatitis B-infected Cells and Enhanced Hepatic Uptake in Mice," <u>Antiviral Research</u> , 59-65, 1994
Ho	C37	Hostetler et al., "Phosphatidylazidothymidine and Phosphatidyl-ddC: Assessment of Uptake in Mouse Lymphoid Tissues and Antiviral Activities in Human Immunodeficiency Virus-Infected Cells and in Rauscher Leukemia Virus-Infected Mice," <u>Antimicrobial Agents and Chemotherapy</u> , Dec. 2792-2797, 1994,
Ho	C38	Hruska, J. F. et al., "In vivo Inhibition of Respiratory Syncytial Virus by Ribavirin," <u>Antimicrob Agents Chemother.</u> , 21:125-130, 1982
Ho	C39	Hsu, L. et al., "Synthesis of Anti-Restricted Pyrimidine Acyclic Nucleosides," <u>Journal of Organic Chemistry</u> , Vol. 57, No. 12, pp. 3354-3358, 1992
Ho	C40	IMPACT RSV Study Group, "Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-Risk Infants," <u>Pediatrics</u> , 102:531-537, 1998
	C41	Jahne et al., "Preparation of Carbocyclic Phosphonate Nucleosides," <u>Tetrahedron Letters</u> , Vol. 33, No. 37, 5333-5338, 1992 — <i>not submitted/available for review</i>
Ho	C42	Jayasuriya et al., Design, Synthesis, and Activity of Membrane-Disrupting Bolaphiles," <u>J. Am. Chem. Soc.</u> , 112, 5844-5850, 1990
Ho	C43	Jia et al., "Diamide Analogues of Phosphatidylcholine as Potential Anti-AIDS Agents," <u>J. Chem. Soc.</u> , 2521-2523, 1993.
Ho	C44	Kakiuchi N. et al., "Non-peptide Inhibitors of HCV Serine Proteinase," <u>J. FEBS Letters</u> , 421:217-220, 1993
Ho	C45	Kasnar, B. et al., "Synthesis of 2',3'-Dideoxy- and 3'-Azido-2',3'-Dideoxy-Pyridazine Nucleosides as Potential Antiviral Agents," <u>Nucleosides & Nucleotides</u> , 13(1-3), pp. 459-479, 1994
Ho	C46	Kawana, F. et al., "Inhibitory Effects of Antiviral Compounds on Respiratory Syncytial Virus Replication In Vitro," <u>Antimicrob Agents Chemother.</u> , August 31, (8):1225-30, 1987
Ho	C47	Korba, B. E. et al., "Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitis B Virus Replication," <u>Antiviral Research</u> , 19, 55-70, 1992
Ho	C48	Krugner-Higby, L., et al., "Membrane-Interactive Phospholipids Inhibit HIV Type 1-Induced Cell Fusion and Surface gp160/gp120 Binding to Monoclonal Antibody," <u>AIDS Research and Human Retroviruses</u> , Vol. 11, 705-712, 1995
Ho	C49	Krugner-Higby, L. A. et al., "Novel Membrane Interactive Ether Lipid Analogs Inhibit HIV-1 Glycoprotein Interaction with CD4 ⁺ Cells," Abstract 321, 32 nd Interscience Conf. on Antimicrobial Agents and Chemotherapy, Anaheim, 164, 11-14 Oct. 1992
Ho	C50	Kucera, L. S., et al., "Activity of Triciribine and Triciribine-5'-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2k" <u>Aids Research and Human Retroviruses</u> , Vol. 9, No. 4, pp. 307-314, 1993

EXAMINER <i>Howard Chung</i>	DATE CONSIDERED <i>12-2-04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

053665-5010-01

APPLICATION NO

09/844,201

APPLICANT


Louis S. KUCERA et al.

FILING DATE

April 27, 2001

GROUP

1623



HO	C51	Kucera, "Effect of Membrane-Active Ether Lipid (EL) Analogues on Human Immunodeficiency Virus Production Measured by Plaque Assay," <u>Annals of the New York Academy of Sciences</u> , 545-548, 26 Dec. 1990
HO	C52	Kucera, "Inhibition of HIV-1 Plaque Formation by a Novel Class of Membrane-Active Ether Lipid Analogs," <u>International Conference on AIDS</u> , Abstract No. W.C.O. 21, p. 528, June 4-9, 1989
HO	C53	Kucera, "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) by Novel Membrane Interactive Ether Lipids," <u>Abstract No. 2470, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416, March 1990
HO	C54	Kucera, L., et al., "Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion by Synthetic Phospholipid Analogs," <u>Antiviral Research</u> , p. A260, 1985
HO	C55	Kucera, "Investigations on Membrane Active Ether Lipid Analogs that Alter Functional Expression of HIV-1 Induces Glycoproteins and Inhibit Pathogenesis," <u>Abstract, Innovations in Therapy of Human Viral Diseases, Symposium, Research Triangle Park</u> , 16, 6-9 Dec. 1992
HO	C56	Kucera, L.S. et al., "In Vitro Evaluation and Characterization of Newly Designed Alkylamidophospholipid Analogues as Anti-Human Immunodeficiency Virus Type 1 Agents," <u>Antiviral Chemistry and Chemotherapy</u> , 9:157-165, 1998
HO	C57	Kucera, L., et al., "Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Virus Activity," <u>Abstract, ICAAC Orlando</u> , 1994
HO	C58	Kucera, L. et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation," <u>AIDS Research And Human Retroviruses</u> , 6, 491-501, 1990
HO	C59	Kumar, R., et al., "Equal Inhibition of HIV Replication by Stereoisomers of Phosphatidyl-Azidothymidine - Lack of Stereospecificity of Lysosomal Phospholipase A ₁ ," <u>The Journal of Biological Chemistry</u> , 267, 20288-20292, 1992
HO	C60	Lister et al., "Cyclopentanoid Analogs of Phosphatidylcholine: Susceptibility to Phospholipase A ₂ ," <u>Journal of Lipid Research</u> , Vol. 29, 1297-1308, 1988.
HO	C61	Maccjak, D. J. et al., "Inhibition of Viral Replication by Nuclease Resistant Hammerhead Biorzymes Directed Against Hepatitis C virus RNA," <u>Hepatology</u> , 30 Abstract 995, 1999
HO	C62	M. MacCoss et al., "Synthesis and Biological Activity of Novel Nucleoside-Phospholipid Prodrugs," <u>4th International Round Table Nucleosides, Nucleotides and their Biological Applications</u> , Antwerp, February 4-6, p. 255-263, February 4-6, 1981
HO	C63	Marasco, Jr., C. J., "The Synthesis and Biological Activity of Novel Alkylglycerol Derivatives as Inhibitors of Protein Kinase C Activity, Neoplastic Cell Growth, and HIV-1 Infectivity," <u>Dissertation for Ph.D., Univ. of No. Carolina, Chapel Hill</u> , 1990
HO	C64	Marasco, C. J. et al., "Synthesis and Biological Activity of Novel Quaternary Ammonium Derivatives of Alkylglycerols as Potent Inhibitors of Protein Kinase C," <u>Journal of Medicinal Chemistry</u> , No. 33, pp. 985-992, March 1990
HO	C65	Marasco et al., "The Synthesis and Biological Testing of Alkyl Glycerols as Potential Inhibitors of Protein Kinase C," <u>American Assoc. of Pharmaceutical Scientists Abstract</u> , Vol. 9, No. 10, 1992

EXAMINER

DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

053665-5010-01

APPLICATION NO

09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE

April 27, 2001

GROUP

1623

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

Ho	C66	Marx, M. H. et al., "Synthesis and Evaluation of Neoplastic Cell Growth Inhibition of 1-N-Alkylamide Analogues of Glycero-3-Phosphocholine," <u>Journal of Medicinal Chemistry</u> , Abstract, 31, 858-863, March 28, 1988
Ho	C67	Meert, K. L. et al., "Aerosolized Ribavirin in Mechanically Ventilated Children with Respiratory Syncytial Virus Lower Respiratory Tract Disease: a Prospective Double-Blind Randomized Trial," <u>Crit Care Med.</u> , Abstract 22:566-572, April 1994
Ho	C68	Mertes et al., "Charge-Spatial Models. cis- and trans-3- and -4- Substituted Cyclohexyl Phosphates as Analogs of 2'-Deoxyuridine 5'-Phosphate," <u>J. Med. Chem.</u> , Vol. 12(5), 828-832, 1968
Ho	C69	Meyer, K. L., et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents," <u>J. Med. Chem.</u> , 34, 1377-1383, 1991
Ho	C70	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Lipids," <u>AAPS Meeting, Atlanta Abstract N. MN-510</u> , p. S-41, 22-25 Oct. 1989
Ho	C71	Miller, R. H., et al., "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses," <u>Proc. Natl. Acad. Sci. USA</u> , 83, pp. 2531-2535, April 1986
Ho	C72	Mitsuya, H. et al., "Strategies for Antiviral Therapy in AIDS," <u>Nature</u> , 325, 773-78, 26 February 1987
Ho	C73	Modest, "Combination Chemotherapy Studies with Antitumor and Antiviral Ether Lipid Analogs," <u>Abstract 2471, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 Abstract 2471, March 1990
Ho	C74	Modest, E., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia," <u>Proceedings of the American Association for Cancer Research: Preclinical Pharmacology Experimental Therapeutics</u> , Vol. 31, pp. 416, Abstract 2467, March 1990
Ho	C75	Modest, E. J. et al., "Pharmacological Effects and Anticancer Activity of New Ether Phospholipid Analogs," <u>The Pharmacological Effect of Lipids III: Role of Lipids in Cancer Research</u> , (IN PRESS), pp. 330-337, 1989
Ho	C76	Molla, A. et al., "Human Serum Attenuates the Activity of Protease Inhibitors Toward Wild-Type and Mutant Human Immunodeficiency Virus," <u>Virology</u> , 250:255-262, 1998
Ho	C77	Morrey, J. D. et al., "Effects of Zidovudine on Friend Virus Complex Infection in Rfv-3 ^{na} Genotype-Containing Mice Used as a Model for HIV Infection," <u>Journal of Acquired Immune Deficiency Syndromes</u> , 3, 500-10, 1990
Ho	C78	Morris-Natschke, S. L. et al., "Synthesis of Phosphocholine and Quaternary Amine Ether Lipids and Evaluation of <i>in Vitro</i> Antineoplastic Activity," <u>J. Med. Chem.</u> , 36:2018-2025, 1993
Ho	C79	Morris-Natschke, S. et al., "Synthesis of Sulfur Analogues of Alkyl Lysophosphospholipid and Neoplastic Cell Growth Inhibitory Properties," <u>J. of Med. Chem.</u> , 29, 2114-17, 1986
Ho	C80	Mufson, M. A. et al., "Two Distinct Subtypes of Human Respiratory Syncytial Virus," <u>The Journal of General Virology</u> , 66:2111-2124, October 1985 <i>Author Mufson, M.A. et al.</i>
Ho	C81	Nara, P. L. et al., "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection of Human Immunodeficiency Virus Neutralizing Antibody," <u>AIDS Research and Human Retroviruses</u> , 3, 283-302, 1987
Ho	C82	Nosedá, A. et al., "In Vitro Antiproliferative Activity of Combinations of Ether Lipid Analogues and DNA-interactive Agents Against Human Tumor Cells," <u>Cancer Research</u> , 48, 1788-1791, April 1, 1988


EXAMINER

DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5010-01	09/844,201
	APPLICANT	
	Louis S. KUCERA et al.	
	FILING DATE	GROUP
	April 27, 2001	1623


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


70	C83	Noseda, A. et al., "Neoplastic Cell Inhibition with New Ether Lipids Analogs," <u>Lipids</u> , 22, 878-883, Nov. 1987
	C84	Ostertag, W. et al., "Induction of Endogenous Virus and of Thymidine Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus," <u>Proc. Nat. Acad. Sci. USA</u> , 71, 4980-85, Dec. 1974
	C85	Pacheco, D. Y. et al., "Mechanisms of Toxicity of Hepsulfam in Human Tumor Cell Lines," Abstract 2446, <u>Proceedings of the American Association for Cancer Research</u> , 81, 412, May 1990
	C86	Painuly et al., "Preparative HPLC of an Experimental Anti-HIV Analogue of AZT: Azidothymidine Monophosphate Diglyceride (AZT-MP-DG)," <u>Journal of Liquid Chromatography</u> , 16(11), 2237-2248, 1993
	C87	Pajouhesh et al., "Synthesis of Polar Head Group Homologs of All-trans-cyclopentano-phosphatidylcholine, Phosphatidyl-N, N-Dimethylethanolamine, and Phosphatidylethanolamine," <u>Journal of Lipid Research</u> , Vol. 25, 294-303, 1984
	C88	Piantadosi, C. et al., "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity," <u>J. Med. Chem.</u> , 34, 1408-14, 1991
	C89	Pidgeon, C. et al., "Anti-HIV Drugs Conjugated to the Glycerobackbone of Phospholipids," <u>The Journal of Biological Chemistry</u> , 7773-7778, 1993
	C90	Pidgeon C. et al., "Novel Acylated Phospholipid Drugs for AIDS," <u>Chemical Abstract</u> , 120:69591, 1994
	C91	The PREVENT Study Group, "Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin: Prophylaxis," <u>Pediatrics</u> , 99:93-99, 1997
	C92	Prince, G. A., "The Pathogenesis of Respiratory Syncytial Virus Infection in Cotton Rats," <u>Am J Pathol Abstract</u> , 93:771-91, 1978
	C93	Qasim M.A. et al., "Interscaffolding Additivity. Association of P ₁ Variants of Eglin c and of Turkey Ovomucoid Third Domain with Serine Proteinases," <u>Biochemistry</u> 36:1598-1607, 1997
	C94	Qiu et al., "Membrane Properties of Antiviral Phospholipids Containing Heteroatoms in the Acyl Chains," <u>Biochemistry</u> , 33(4), 960-72, 1994
	C95	C. Raetz et al., "Phospholipid Derivative of Cytosine Arabinoside and its Conversion to Phosphatidylinositol by Animal Tissue," <u>Science</u> 196, 303-304, 1977
	C96	Rodriguez, W. J. et al., "Prospective Follow-Up and Pulmonary Functions from a Placebo-Controlled Randomized Trial of Ribavirin Therapy in Respiratory Syncytial Virus Bronchiolitis," <u>Arch Pediatr Adolesc Med</u> , 153:469-474, May 1999
	C97	Runge et al., "Destruction of Human solid Tumors by Alkyl Lyso Phospho Lipids," <u>Journal of the National Cancer Institute</u> , Vol. 64, 1301-1306, 1980
	C98	Sable, C. A. et al., "Orthomyxoviral and Paramyxoviral Infections in Transplant Patients," <u>Infect Dis Clin North Am</u> , Abstract, 9:987-1003, December 1995
	C99	Sarin, P. S. et al., "Effects of a Novel Compound (AL 721) on HTLV-III Infectivity in Vitro," <u>The New England Journal of Medicine</u> , Vol. 313, 1289-90, Nov. 14, 1985
	C100	Scolaro M. J. et al., "Inhibition of Virus Replication with Oligonucleotides," <u>Chemical Abstracts</u> , 117:124476, 1992
	C101	Sidoti et al., "Cytostatic Activity of New Synthetic Anti-Tumor AZA-Alkyllysophospholipids," <u>Int. J. Cancer</u> 51, 712-717, 1992
70	C102	Small, "Characterization of Cells Sensitive and Resistant to ET-18-OCH ₃ ," Abstract 2447, <u>Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416, March 1990

EXAMINER


DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)



ATTY DOCKET NO.

053665-5010-01

APPLICATION NO

09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE

April 27, 2001

GROUP

1623

Ho	C103	Smith, D. W. et al., "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection," <u>New England Journal of Medicine</u> , 325:24-29, July 1991
Ho	C104	Steim et al., "Lipid Conjugates of Antiretroviral Agents. I. Azidothymidine-Monophosphate-Diglyceride: Anti-HIV Activity, Physical Properties, and Interaction with Plasma Proteins," <u>Biochemical and Biophysical Research Communications</u> , Vol. 171, No. 1, 451-457, 1990
Ho	C105	Sudo K. et al., "Inhibitory Effects of Podophyllotoxin Derivatives on Herpes Simplex Virus Replication," <u>Antiviral Chemistry and Chemotherapy</u> 9:186, 1998
Ho	C106	Sudo K. et al., "Establishment of an In Vitro System for Screening Hepatitis C Virus Protease Inhibitors Using High Performance Liquid Chromatography," <u>Antiviral Research</u> 32:9-18, 1996
Ho	C107	Sunamoto, J. et al., "Induction of Cytotoxic T Cell," <u>Chemical Abstracts</u> , 117:68365, 1992
Ho	C108	Surles, J. R. et al., "Multigram Synthesis of 1-Alkylamido Phospholipids," <u>Lipids</u> , 28, 55-57, 1993
Ho	C109	Swayze, E. E., et al., "Synthesis of 1-(2-Aminopropyl) Benzimidazoles, Structurally Related to the Tibo Derivative R82150, With Activity Against Human Immunodeficiency Virus," <u>Bioorganic & Medical Chemistry Letters</u> , Vol. 3, No. 4, pp 543-546, 1993
Ho	C110	Takeshita N. et al., "An Enzyme-Linked Immunosorbent Assay for Detecting Proteolytic Activity of Hepatitis C Virus Proteinase," <u>Analytical Biochemistry</u> 247:242-246, May 1, 1997
Ho	C111	Tarnowski et al., "Effect of Lyso Lecithin and Analogs on Mouse Ascites," <u>Cancer Research</u> , Vol. 38, 339-344, 1978
Ho	C112	Thompson, J., et al., "Phospholipid Analog Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion," <u>Abstracts of the 2nd National Conference on Human Retroviruses</u> , Session 18, 1995
Ho	C113	Tiollais, P., et al., "Hepatitis B. Virus," <u>Scientific American</u> , 116-123, April 1991
Ho	C114	Van Wijk et al., "Synthesis and Antiviral Activity of 3'-azido-3'-deoxythymidine Triphosphate Distearoylglycerol: A Novel Phospholipid Conjugate of the Anti-HIV Agent AZT," <u>Chemistry and Physics of Lipids</u> , 70, 213-222, 1994
Ho	C115	Van Wijk, G. M. et al., "Spontaneous and Protein-Mediated Intermembrance Transfer of the Antiretroviral Liponucleotide 3'-Deoxythymidine Diphosphate Diglyceride," <u>Biochemistry</u> , 31, 5912-5917, June 30, 1992
Ho	C116	Vos, G. D. et al., "Treatment of Respiratory Failure Due to Respiratory Syncytial Virus Pneumonia with Natural Surfactant," <u>Pediatr Pulmonol.</u> , Abstract 22:412-415, December 1996
Ho	C117	Wang, E. E. et al., "Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Prospective Study of Risk Factors and Outcomes in Patients Hospitalized with Respiratory Syncytial Viral Lower Respiratory Tract Infection," <u>Abstract, J Pediatr</u> , 126:212-219, February 1995
Ho	C118	Whimbey, E. et al., "Community Respiratory Virus Infections Among Hospitalized Adult Bone Marrow Transplant Recipients," <u>Abstract, Clin Infect Dis.</u> , 22:778-782, May 1996
Ho	C119	Yamaue, H. et al., "Chemosensitivity Testing with Highly Purified Fresh Human Tumor Cells with the MTT Colorimetric Assay," <u>Abstract, Eur J Cancer</u> , 27:1258-1263, 1991
Ho	C120	Yanagawa, H. et al., "Spontaneous Formation of Superhelical Strands," <u>Journal of the American Chemical Society</u> , 111, 4567-70, June 21, 1989
Ho	C121	Yarchoan, R. et al., "Therapeutic Strategies in the Treatment of AIDS," <u>Annual Reports in Medicinal Chemistry</u> , Vol. 23, 253-263, 1988

EXAMINER

Howard Chen

DATE CONSIDERED

12-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PLEASE STAMP AND RETURN TO SHOW RECEIPT OF:

U.S. Patent Application No.: 09/844,201

Applicants: Kucera, et al.

Group Art Unit: 1623

Filed: April 27, 2001

Examiner: Unknown

Title: COMPOSITIONS AND METHODS OF DOUBLE-TARGETING
VIRUS INFECTIONS AND CANCER CELLS

BEST AVAILABLE COPY


The Patent and Trademark Office acknowledges, and has
stamped hereon, the date of the receipt of the items listed below:

1. Information Disclosure Statement (3 pages).
2. PTO Form 1449 (1 page).
3. References (5).

Date: August 27, 2003

Atty. Docket No.: 053665-5010-01

KRJ



PLEASE STAMP AND RETURN TO SHOW RECEIPT OF:

U.S. Patent Application No.: 09/844,201


Applicants: Kucera, et al.

Group Art Unit: 1623

Filed: April 27, 2001

Examiner: Unknown

Title: COMPOSITIONS AND METHODS OF DOUBLE-TARGETING
VIRUS INFECTIONS AND CANCER CELLS



The Patent and Trademark Office acknowledges, and has
stamped hereon, the date of the receipt of the items listed below:


1. Information Disclosure Statement (3 pages).
2. PTO Form 1449 (1 page).
3. References (5).

Date: August 27, 2003

Atty. Docket No.: 053665-5010-01

KRJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:

Louis S. Kucera, et al.

Application No.: 09/844,201

Filed: April 27, 2001

For: COMPOSITIONS AND METHODS FOR
DOUBLE-TARGETING VIRUS INFECTIONS
AND TARGETING CANCER CELLS

Group Art Unit: 1623

Examiner: Unknown

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56 ET SEQ.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. § 1.97(b), the above-identified Applicants cite the following patents and publications, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits and each item was cited in an International Search Report dated June 13, 2003 for a counterpart application not more than three months prior to the filing date of this Information Disclosure Statement.

CERTIFICATE OF MAILING (37 C.F.R. § 1.8)

I hereby certify that this paper, and the papers and/or fees referred to herein as transmitted, submitted or enclosed, are being deposited on the date shown below with the U.S. Postal Service with sufficient postage as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Name Kim R. Jessum Signature *Kim R. Jessum* Date of Deposit August 27, 2003

In compliance with 37 C.F.R. § 1.98(a), copies of the patents and publications set forth below and listed on the attached Form PTO-1449 (1 sheet) are provided.

U.S. Patents

<u>Patent No.</u>	<u>Issue Date</u>	<u>Patentee</u>
5,512,671	4/30/96	Piantadosi, et al.

Other Publications

HENDRICKSON, H., et al., A Facile Asymmetric Synthesis of Glycerol Phospholipid via Tritylglycidol Prepared by the Asymmetric Epoxidation of Allyl Alcohol. Chem. Phys. Lipids, 1990, Vol. 53, No. 1, pages 115-20, Abstract.

GORDEEV, K., et al., Synthesis of Thio Analogs of Platelet Activating Factor (PAF), Bioorg. Khim., 1986, Vol. 12, No. 7, pages 951-955, Abstract.

HONG, C., et al., Nucleoside Conjugates. 15. Synthesis and Biological Activity of Anti-HIV Nucleoside Conjugates of Ether and Thioether Phospholipids, J. Med. Chem., 1996, Vol. 39, No. 9, pages 1771-1777, Abstract.

HONG, C., et al., Nucleoside-Ether Lipid Conjugates as Biotransformed Prodrugs of Antitumor and Antiviral Nucleosides, J. Lipid Mediators Cell Singaling, 1994, Vol. 10, No. 1-2, pages 159-161, Abstract.

Applicant respectfully requests that these items be considered by the Examiner, and that the Examiner acknowledge consideration of these references by initialing and returning copies of the enclosed Form PTO-1449 (1 sheet) with the next official action.

While this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" for this invention or otherwise material to the patentability of this invention as defined in 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

August 27, 2013
Date

By: Kim R. Jessum

Kim R. Jessum
Reg. No. 43,694
Customer No. 028977
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-4753
Facsimile: (215) 963-5299


INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete Known

Application Number 09/844,201
 Filing Date April 27, 2001
 First Named Inventor Kucera, et al.
 Group Art Unit 1623
 Examiner Name Unknown
 Attorney Docket Number 053665-5010-01



U.S. PATENT DOCUMENTS

Exr Initials	U.S. Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Number	Kind Code (if known)		
	5,512,671		Piantadosi, et al.	04-30-1996

FOREIGN PATENT DOCUMENTS

Exr Initials	Foreign Patent Document			Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ₁
	Country Code	Number	Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ₁
	HENDRICKSON, H., et al., A Facile Asymmetric Synthesis of Glycerol Phospholipid via Tritylglycidol Prepared by the Asymmetric Epoxidation of Allyl Alcohol. Chem. Phys. Lipids, 1990, Vol. 53, No. 1, pages 115-20, Abstract.	
	GORDEEV, K., et al., Synthesis of Thio Analogs of Platelet Activating Factor (PAF), Bioorg. Khim., 1986, Vol. 12, No. 7, pages 951-955, Abstract.	
	HONG, C., et al., Nucleoside Conjugates. 15. Synthesis and Biological Activity of Anti-HIV Nucleoside Conjugates of Ether and Thioether Phospholipids, J. Med. Chem., 1996, Vol. 39, No. 9, pages 1771-1777, Abstract.	
	HONG, C., et al., Nucleoside-Ether Lipid Conjugates as Biotransformed Prodrugs of Antitumor and Antiviral Nucleosides, J. Lipid Mediators Cell Singaling, 1994, Vol. 10, No. 1-2, pages 159-161, Abstract.	

Examiner
SignatureDate
Considered